Abstract
The coronavirus disease 2019 (COVID-19) pandemic has prompted the creation of new therapies to help fight against the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Bamlanivimab is a SARS-CoV-2 monoclonal antibody that is administered as an intravenous infusion to ambulatory patients with mild or moderate COVID-19, but a concern that arose was deciding the optimal location for patients to receive the medication. This report describes the development and implementation of a bamlanivimab infusion center in the emergency department of three hospitals in Orange County, California, shortly after bamlanivimab received emergency use authorization. As a result, a total of 601 patients received bamlanivimab in one of these three emergency departments between December 2020 to April 2021. The emergency department was shown to be an optimal setting for administration of bamlanivimab due to its convenience, accessibility, and capabilities for monitoring patients.
Highlights
The coronavirus disease 2019 (COVID-19) pandemic has resulted in over 247 million cases of infection and over 5 million deaths [1]
The implementation of a COVID-19 monoclonal antibody infusion program in the emergency department (ED) was established at three hospitals in California: Providence Mission Hospital Mission Viejo (Mission Viejo, CA, USA), Providence Mission Hospital Laguna Beach (Laguna Beach, CA, USA), and the University of California, Irvine Medical Center (Orange, CA, USA)
The bamlanivimab infusion workflow was implemented on 20 December 2020 at Providence Mission Hospital Mission Viejo (MHMV) and Mission Hospital Laguna Beach (MHLB) locations
Summary
The coronavirus disease 2019 (COVID-19) pandemic has resulted in over 247 million cases of infection and over 5 million deaths [1] This public health crisis has encouraged prompt responses to discover new agents and therapies that may prevent or treat COVID-19 caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Bamlanivimab is a recombinant human immune globulin G kappa (IgG1κ) monoclonal antibody that is derived from convalescent plasma [4]. It neutralizes the surface spike glycoprotein of SARS-CoV-2, preventing spike protein attachment to the human angiotensin-converting enzyme 2 (ACE2) receptor and preventing entry of the virus into human cells [5]. COVID-19-related hospitalizations at day 29 were 1.6% in the bamlanivimab group vs. 6.3% in the placebo group [6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
